Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Debt Ratio (2016 - 2021)

Lineage Cell Therapeutics' Debt Ratio history spans 6 years, with the latest figure at 0.0 for Q1 2021.

  • For Q1 2021, Debt Ratio changed N/A year-over-year to 0.0; the TTM value through Mar 2021 reached 0.0, changed N/A, while the annual FY2020 figure was 0.0, N/A changed from the prior year.
  • Debt Ratio reached 0.0 in Q1 2021 per LCTX's latest filing, down from 0.0 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.01 in Q3 2020 to a low of 0.0 in Q4 2017.
  • Average Debt Ratio over 3 years is 0.0, with a median of 0.0 recorded in 2021.
  • The largest YoY upside for Debt Ratio was 70.37% in 2017 against a maximum downside of 87.66% in 2017.
  • A 3-year view of Debt Ratio shows it stood at 0.0 in 2017, then surged by 4562.96% to 0.0 in 2020, then dropped by 15.62% to 0.0 in 2021.
  • Per Business Quant, the three most recent readings for LCTX's Debt Ratio are 0.0 (Q1 2021), 0.0 (Q4 2020), and 0.01 (Q3 2020).